Objective: To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).
Methods: BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at https://biobadaguay.ser.es. Variables associated with the safety of the therapies were used for the present study. The incidence of AA was calculated as incidence rate (IR) per 1000 patient-years, with 95% confidence intervals (CI) and Poisson regression for the incidence rate ratio (IRR).
Results: 1104 patients (73.3% female) with 1366 AA, predominantly mild (87.2%), were analyzed. The overall incidence of AEs was 251.75 per 1000 patient-years. Infections were the most frequent (55.0%), with an incidence of 138.4 per 1000 patient-years. Rheumatoid arthritis and corticosteroid use were associated with more global AEs, while anti-TNF was associated with less AEs.
Conclusions: This study from the BIOBADAGUAY registry has provided valuable data on the safety of DMARD-b, sd in a cohort of patients with inflammatory rheumatic diseases. The incidence of predominantly mild AEs, with infections as the most frequent adverse event, underscores the need for rigorous and constant monitoring in this population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.reumae.2025.101798 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry.
Reumatol Clin (Engl Ed)
February 2025
Hospital Central del Instituto de Previsión Social, Servicio de Reumatología, Asunción, Paraguay; Hosplital de Clínicas, Universidad Nacional de Asunción, Facultad de Ciencias Médicas, Departamento de Reumatología, San Lorenzo, Paraguay.
Objective: To analyze the safety of biologic (DMARDs-b) and synthetic targeted therapies (DMARDs-sd) in the BIOBADAGUAY registry (Paraguayan-Uruguayan registry of adverse events (AEs) in patients with inflammatory rheumatic diseases).
Methods: BIOBADAGUAY is a registry to prospectively evaluate the efficacy and safety of FAME-b and FAME-sd. The full methodology is available at https://biobadaguay.
Pan American League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis.
J Rheumatol
June 2024
E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Objective: Psoriatic arthritis (PsA) is chronic disease that compromises multiple domains and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective was to generate evidence-based recommendations on the management of PsA in Pan American League of Associations for Rheumatology (PANLAR) countries.
Methods: We used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)-ADOLOPMENT approach to adapt the 2019 recommendations of the European Alliance of Associations for Rheumatology.
Safety and Survival Associated with Biologic Therapies: First Report of the Biobadaguay on the Paraguayan-Uruguayan Registry of Adverse Events with Biologic Therapies.
Reumatol Clin (Engl Ed)
September 2021
Hospital Central del Instituto de Previsión Social, Asunción, Paraguay.
Objective: Analyze adverse events (AE) and survival associated with biologic therapies (BT) in the Biobadaguay, the Paraguayan Uruguayan registry of adverse events.
Methods: Prospective, observational study of undetermined duration. Patients on BT at initiation and controls were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!